全文获取类型
收费全文 | 21851篇 |
免费 | 2783篇 |
国内免费 | 242篇 |
专业分类
耳鼻咽喉 | 83篇 |
儿科学 | 353篇 |
妇产科学 | 291篇 |
基础医学 | 1136篇 |
口腔科学 | 574篇 |
临床医学 | 6069篇 |
内科学 | 1624篇 |
皮肤病学 | 166篇 |
神经病学 | 1060篇 |
特种医学 | 338篇 |
外科学 | 2514篇 |
综合类 | 3475篇 |
一般理论 | 1篇 |
预防医学 | 4223篇 |
眼科学 | 150篇 |
药学 | 1531篇 |
159篇 | |
中国医学 | 598篇 |
肿瘤学 | 531篇 |
出版年
2024年 | 54篇 |
2023年 | 457篇 |
2022年 | 720篇 |
2021年 | 1209篇 |
2020年 | 1269篇 |
2019年 | 1183篇 |
2018年 | 1091篇 |
2017年 | 1068篇 |
2016年 | 1105篇 |
2015年 | 983篇 |
2014年 | 1576篇 |
2013年 | 2101篇 |
2012年 | 1200篇 |
2011年 | 1325篇 |
2010年 | 1067篇 |
2009年 | 1098篇 |
2008年 | 1117篇 |
2007年 | 1076篇 |
2006年 | 890篇 |
2005年 | 750篇 |
2004年 | 581篇 |
2003年 | 444篇 |
2002年 | 356篇 |
2001年 | 320篇 |
2000年 | 332篇 |
1999年 | 233篇 |
1998年 | 204篇 |
1997年 | 184篇 |
1996年 | 118篇 |
1995年 | 98篇 |
1994年 | 72篇 |
1993年 | 72篇 |
1992年 | 78篇 |
1991年 | 45篇 |
1990年 | 46篇 |
1989年 | 34篇 |
1988年 | 47篇 |
1987年 | 34篇 |
1986年 | 19篇 |
1985年 | 31篇 |
1984年 | 42篇 |
1983年 | 19篇 |
1982年 | 25篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 12篇 |
1978年 | 16篇 |
1977年 | 15篇 |
1976年 | 9篇 |
1975年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
Gaurav Gupta Idris Yakubu Chandra S. Bhati Yiran Zhang Le Kang Julie A. Patterson Ayana Andrews‐Joseph Anam Alam Andrea Ferreira‐Gonzalez Dhiren Kumar Irfan K. Moinuddin Layla Kamal Anne L. King Marlon Levy Amit Sharma Adrian Cotterell Trevor W. Reichman Aamir Khan Pamela Kimball Rodney Stiltner Mary Baldecchi Nathaniel Brigle Todd Gehr Richard K. Sterling 《American journal of transplantation》2020,20(3):739-751
We conducted an adaptive design single‐center pilot trial between October 2017 and November 2018 to determine the safety and efficacy of ultra‐short‐term perioperative pangenotypic direct acting antiviral (DAA) prophylaxis for deceased hepatitis C virus (HCV)‐nucleic acid test (NAT) positive donors to HCV negative kidney recipients (D+/R?). In Group 1, 10 patients received one dose of SOF/VEL (sofusbuvir/velpatasvir) pretransplant and one dose on posttransplant Day 1. In Group 2A (N = 15) and the posttrial validation (Group 2B; N = 25) phase, patients received two additional SOF/VEL doses (total 4) on Days 2 and 3 posttransplant. Development of posttransplant HCV transmission triggered 12‐week DAA therapy. For available donor samples (N = 27), median donor viral load was 1.37E + 06 IU/mL (genotype [GT]1a: 70%; GT2: 7%; GT3: 23%). Overall viral transmission rate was 12% (6/50; Group 1:30% [3/10]; Group 2A:13% [2/15]; Group 2B:4% [1/25]). For the 6 viremic patients, 5 (83%) achieved sustained virologic response (3 with first‐line DAA therapy; and two after retreatment with second‐line DAA). At a median follow‐up of 8 months posttransplant, overall patient and allograft survivals were 98%, respectively. The 4‐day strategy reduced viral transmission to 7.5% (3/40; 95% confidence interval [CI]: 1.8%‐20.5%) and could result in avoidance of prolonged posttransplant DAA therapy for most D+/R ? transplants. 相似文献
993.
Flavio Vincenti Goran Klintmalm Harold Yang V. Ram Peddi Paul Blahunka Angela Conkle Vicki Santos John Holman 《American journal of transplantation》2020,20(1):172-180
This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of various doses of the anti‐CD40 monoclonal antibody bleselumab (ASKP1240) in de novo kidney transplant recipients receiving concomitant standard immunosuppression over 90 days posttransplant. Transplant recipients were randomized (1:1:1:1:1) to bleselumab 50 mg, 100 mg, 200 mg, or 500 mg, or placebo, in addition to standard maintenance immunosuppression. The primary pharmacokinetic endpoints were AUCinf, Cmax, and AUClast. The primary pharmacodynamic endpoint was B cell CD40 receptor occupancy over time. Overall, 50 kidney transplant recipients were randomized; 45 received their randomized treatment (bleselumab [n = 37] or placebo [n = 8]). AUCinf and AUClast demonstrated a more than dose‐proportional increase in the range of 50‐500 mg, and Cmax increased linearly with increasing dose. Maximal receptor occupancy for B cell CD40 was reached at all dose levels and was prolonged as dose increased. No kidney transplant recipients experienced cytokine release syndrome or a thromboembolic event. Treatment‐emergent anti‐bleselumab antibodies were found in one kidney transplant recipient in the bleselumab 50 mg group; these were detected only at Day 7. Overall, bleselumab demonstrated nonlinear pharmacokinetics and dose‐dependent prolonged B cell CD40 receptor occupancy and was well tolerated at all doses (ClinicalTrials.gov: NCT01279538). 相似文献
994.
Francesco Procaccio Lucia Masiero Francesca Vespasiano Paolo A. Grossi Carlo Gagliotti Annalisa Pantosti Mario Caprio Letizia Lombardini Alessandro Nanni Costa 《American journal of transplantation》2020,20(1):262-273
The 759 cases of brain death declaration (BDD [Italian law, 6 hours of observation time]) that occurred in 190 Italian intensive care units (ICUs) between May and September 2012 were studied to quantify carbapenem‐resistant gram‐negative bacteria (CR‐GN) isolated in organ donors, to evaluate adherence to national screening guidelines, and to identify risk factors for CR‐GN isolation. Mandatory blood, bronchoalveolar lavage, and urine cultures were performed on the BDD day in 99% of used donors. Because results were rarely made available before transplant, >20% of transplants were performed before obtaining any microbiological information, and organs from 15 of 22 CR‐GN cases were used. Two (lung–liver) of the 37 recipients died, likely because of donor‐derived early CR‐GN sepsis. ICU stay >3 days (odds ratio [OR] = 7.49, P = .004), fever (OR = 3.11, P = .04), age <60 years (OR = 2.80, P = .06), and positive ICU epidemiology (OR = 8.77, P = .07) were associated with CR‐GN isolation. An association between single ICU and risk of CR‐GN was observed, as a result of differences across ICUs (ICC = 29%; 95% confidence interval [CI] 6.5%‐72%) probably related to inadequate practices of infection control. Continuous education aimed at implementing priority actions, including stewardship programs for a rational use of antimicrobials, is a priority in healthcare systems and transplant networks. Improved awareness among ICU personnel regarding the importance of early CR‐GN detection and timely alert systems might facilitate decisions regarding organ suitability and eventually save recipient lives. 相似文献
995.
Simon Tremblay James J. Driscoll Adele Rike‐Shields David A. Hildeman Rita R. Alloway Alin L. Girnita Paul A. Brailey E. Steve Woodle 《American journal of transplantation》2020,20(2):411-421
Proteasome inhibitor–based strategies hold promise in transplant but have yielded varying results. Carfilzomib, a second‐generation proteasome inhibitor, may possess advantages over bortezomib, the first‐generation proteasome inhibitors. The purpose of this study was to evaluate the safety, toxicity, and preliminary efficacy of carfilzomib in highly HLA‐sensitized kidney transplant candidates. Renal transplant candidates received escalating doses of carfilzomib followed by plasmapheresis (group A) or an identical regimen with additional plasmapheresis once weekly before carfilzomib dosing. Thirteen participants received carfilzomib, which was well tolerated with most adverse events classified as low grade. The safety profile was similar to bortezomib desensitization; however, neurotoxicity was not observed with carfilzomib. Toxicity resulted in permanent dose reduction in 1 participant but caused no withdrawals or deaths. HLA antibodies were substantially reduced with carfilzomib alone, and median maximal immunodominant antibody reduction was 72.8% (69.8% for group A, P = .031, 80.1% for group B, P = .938). After depletion, rebound occurred rapidly and antibody levels returned to baseline between days 81 and 141. Bone marrow studies revealed that approximately 69.2% of plasma cells were depleted after carfilzomib monotherapy. Carfilzomib monotherapy–based desensitization provides an acceptable safety and toxicity profile while leading to significant bone marrow plasma cell depletion and anti‐HLA antibody reduction. 相似文献
996.
Kathryn H. Blew Annabelle Chua John Foreman Rasheed Gbadegesin Annette Jackson Shashi Nagaraj Rebecca Sadun Del Wigfall Allan D. Kirk Eileen T. Chambers 《American journal of transplantation》2020,20(3):884-888
Adolescent transplant recipients are at risk for nonadherence, development of de novo donor‐specific antibody (dnDSA), and allograft loss. Belatacept, a selective T cell costimulatory blocker, is associated with reduced dnDSA, improved renal function, and prolonged allograft survival when compared to calcineurin inhibitor‐based regimens in adults; however, its use in children is scant. Three adolescents were initiated on belatacept between August 2017 and September 2018 at the time of kidney transplantation. Selection criteria included age ≥ 14 and EBV IgG + serostatus. Intraoperative alemtuzumab and methylprednisolone were given as induction therapy. Tailored maintenance therapy included steroid‐free belatacept and sirolimus for two patients. One patient was initially maintained steroid‐free on belatacept and belimumab, an inhibitor of B cell activating factor to treat concurrent systemic lupus erythematous; steroids were added subsequently. Renal function, biopsy‐proven rejection, dnDSA, allograft survival, infection, nonadherence, and proteinuria were monitored. Renal function was 86, 73, 52 mL/min/1.73 m2 at 20, 20, and 8 months, respectively. There was 100% adherence to therapy and no development of dnDSA. All patients had treatable infections. One developed steroid‐responsive acute cellular rejection. Belatacept‐based regimens can be tailored for adolescent recipients with good short‐term clinical outcomes. 相似文献
997.
Nikhil Kapila Kawtar Al‐Khalloufi Pablo A. Bejarano Jason M. Vanatta Xaralambos B. Zervos 《American journal of transplantation》2020,20(2):600-605
Fibrosing cholestatic hepatitis (FCH) posttransplantation can lead to graft failure and death. In the era of direct acting antiviral therapy (DAA), several studies have demonstrated the efficacy and safety of transplanting hepatitis C virus (HCV)–positive allografts into HCV‐negative recipients. In this case series, we present two cases of HCV‐negative recipients who underwent kidney transplantation from viremic donors and developed FCH. Both patients presented after transplant with abnormal liver function tests and HCV viral loads of greater than 100 000 000 IU/mL. FCH was diagnosed by histology and/or clinical data. Both patients were started on DAA therapy within 24 hours of admission with improvement in LFTs. One patient has undetectable HCV 12 weeks after completing treatment and the other patient has undetectable HCV after completing DAA treatment. The introduction of DAAs has changed the landscape of solid organ transplantation with the potential to expand the donor pool and increase access to organs. While HCV viremic organs have tremendous potential to increase access to a scarce resource, FCH is a potentially fatal complication and therefore clinicians must maintain a high index of suspicion for this unique complication. 相似文献
998.
Jesse D. Schold Joshua J. Augustine Anne M. Huml John OToole John R. Sedor Emilio D. Poggio 《American journal of transplantation》2020,20(3):769-778
Success of transplantation is not limited to initial receipt of a donor organ. Many kidney transplant recipients experience graft loss following initial transplantation and the benefits of expedited placement on the waiting list and retransplantation extend to this population. Factors associated with access to repeat transplantation may be unique given experience with the transplant process and prior viability as a candidate. We examined the incidence, risk factors, secular changes, and center‐level variation of preemptive relisting or transplantation (PRLT) for kidney transplant recipients in the United States with graft failure (not due to death) using Scientific Registry of Transplant Recipients data from 2007 to 2018 (n = 39 557). Overall incidence of PRLT was 15% and rates of relisting declined over time. Significantly lower PRLT was evident among patients who were African American and Hispanic, males, older, obese, publicly insured, had lower educational attainment, were diabetic, had longer dialysis time prior to initial transplant, shorter graft survival, longer distance to transplant center, and resided in distressed communities. There was significant variation in PRLT by center, median = 13%, 10th percentile = 6%, 90th percentile = 24%. Cumulatively, results indicate that despite prior access to transplantation, incidence of PRLT is modest with pronounced clinical, social, and center‐level sources of variation suggesting opportunities to improve preemptive care among patients with failing grafts. 相似文献
999.
Macey L. Henderson Rebecca Hays Sarah E. Van Pilsum Rasmussen Didier A. Mandelbrot Krista L. Lentine Daniel G. Maluf Madeleine M. Waldram Matthew Cooper 《American journal of transplantation》2020,20(2):546-552
Although minimized by expert evaluation, operative technique, and postoperative care, the extremely low risk of perioperative mortality following living kidney or liver donation will never be eliminated. Furthermore, anticipation of poor donor outcome may simultaneously be a source of anxiety for physicians and programs and also be a circumstance for which they are unprepared. We conducted a national survey of US transplant surgeons to understand experiences with and systemic preparedness for the event of a living donor death. Respondents represented 87 unique transplant programs (71 kidney and 16 liver donor programs). Perioperative deaths were rare, as expected. Although most respondents (N = 57, 64% of total respondents; 88% of liver programs) reported being moderately to extremely concerned about a future living donor death at their institution, only 30 (33% of total program respondents) had a written plan available in the case of such an event; 63% of programs would find guidance and recommendations useful. To help address this gap, the American Society of Transplantation Live Donor Community of Practice (AST LDCOP) developed Living Donor Crisis Management Plan Talking Points suitable to guide crisis plan development at transplant programs. 相似文献
1000.
Caio Rebouas Fonseca Cafezeiro Mariana Pezzute Lopes Caio Tavares Silva Mnica Samuel vila Luis Fernando B. C. Seguro Sandrigo Mangini Iscara Wozniak Campos Fbio A. Gaiotto Fabiana G. Marcondes‐Braga Fernando Bacal 《American journal of transplantation》2020,20(5):1451-1453
Epipericardial fat necrosis is an uncommon clinical condition of unknown etiology. It typically presents as acute pleuritic chest pain and should be differentiated from acute pulmonary embolism and acute coronary syndrome. This condition is diagnosed by characteristic chest computed tomography findings of an ovoid mediastinal fatty lesion with intrinsic and surrounding soft‐tissue stranding. Treatment of epipericardial fat necrosis includes the administration of anti‐inflammatory agents, and symptoms usually resolve within a few days after treatment initiation. This disease entity has rarely been reported since it was first described in 1957. Most current knowledge of epipericardial fat necrosis is based on case reports that describe this condition in previously healthy individuals. We present the case of a 39‐year‐old woman with a history of heart transplant, who presented with chest pain secondary to epipericardial fat necrosis. Serial computed tomography revealed lesion resolution after appropriate treatment. 相似文献